MedKoo Cat#: 128152 | Name: SEL24-B489
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SEL24-B489 is a potent, dual pan-PIM/FLT3 inhibitor. SEL24-B489 exhibited significantly broader on-target activity in AML cell lines and primary AML blasts than selective FLT3-ITD or PIM inhibitors. SEL24-B489 also demonstrated marked activity in cells bearing FLT3 tyrosine kinase domain (TKD) mutations that lead to FLT3 inhibitor resistance. Moreover, SEL24-B489 inhibited the growth of a broad panel of AML cell lines in xenograft models with a clear pharmacodynamic-pharmacokinetic relationship.

Chemical Structure

SEL24-B489
SEL24-B489
CAS#1616359-00-2 (free base)

Theoretical Analysis

MedKoo Cat#: 128152

Name: SEL24-B489

CAS#: 1616359-00-2 (free base)

Chemical Formula: C15H18Br2N4O2

Exact Mass: 443.9797

Molecular Weight: 446.14

Elemental Analysis: C, 40.38; H, 4.07; Br, 35.82; N, 12.56; O, 7.17

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 Weeks
25mg USD 950.00 2 Weeks
100mg USD 1,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Synonym
MEN1703; SEL24; SEL24-B489; SEL 24-B489; SEL-24-B489;
IUPAC/Chemical Name
5,6-dibromo-1-isopropyl-4-nitro-2-(piperidin-4-yl)-1H-benzo[d]imidazole
InChi Key
UOUBCIJIWDLRGM-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H18Br2N4O2/c1-8(2)20-11-7-10(16)12(17)14(21(22)23)13(11)19-15(20)9-3-5-18-6-4-9/h7-9,18H,3-6H2,1-2H3
SMILES Code
CC(N1C(C2CCNCC2)=NC3=C([N+]([O-])=O)C(Br)=C(Br)C=C31)C
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 446.14 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wu M, Li C, Zhu X. FLT3 inhibitors in acute myeloid leukemia. J Hematol Oncol. 2018 Dec 4;11(1):133. doi: 10.1186/s13045-018-0675-4. PMID: 30514344; PMCID: PMC6280371. 2: Czardybon W, Windak R, Gołas A, Gałęzowski M, Sabiniarz A, Dolata I, Salwińska M, Guzik P, Zawadzka M, Gabor-Worwa E, Winnik B, Żurawska M, Kolasińska E, Wincza E, Bugaj M, Danielewicz M, Majewska E, Mazan M, Dubin G, Noyszewska-Kania M, Jabłońska E, Szydłowski M, Sewastianik T, Puła B, Szumera- Ciećkiewicz A, Prochorec-Sobieszek M, Mądro E, Lech-Marańda E, Warzocha K, Tamburini J, Juszczyński P, Brzózka K. A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. Oncotarget. 2018 Mar 30;9(24):16917-16931. doi: 10.18632/oncotarget.24747. PMID: 29682194; PMCID: PMC5908295. 3: Białopiotrowicz E, Górniak P, Noyszewska-Kania M, Puła B, Makuch-Łasica H, Nowak G, Bluszcz A, Szydłowski M, Jabłonska E, Piechna K, Sewastianik T, Polak A, Lech-Marańda E, Budziszewska BK, Wasylecka-Juszczyńska M, Borg K, Warzocha K, Czardybon W, Gałęzowski M, Windak R, Brzózka K, Juszczyński P. Microenvironment- induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. J Cell Mol Med. 2018 Jul;22(7):3548-3559. doi: 10.1111/jcmm.13632. Epub 2018 Apr 17. PMID: 29665227; PMCID: PMC6010703. 4: Szydłowski M, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Derezińska E, Hoser G, Wasilewska D, Szymańska-Giemza O, Jabłońska E, Białopiotrowicz E, Sewastianik T, Polak A, Czardybon W, Gałęzowski M, Windak R, Zaucha JM, Warzocha K, Brzózka K, Juszczyński P. Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood. 2017 Sep 21;130(12):1418-1429. doi: 10.1182/blood-2017-01-760702. Epub 2017 Jul 11. PMID: 28698206.